The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: Lineage specificity and clinical correlates

British Journal of Haematology

Volumn 131, Issue 3, 2005, Pages 320-328

  Tefferi, Ayalew ^a   Lasho, Terra L ^a   Schwager, Susan M ^a   Steensma, David P ^a   Mesa, Ruben A ^a   Li, Chin Yang ^a   Wadleigh, Martha ^b   Gary Gilliland, D ^b  

^a MAYO CLINIC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clonality; JAK2; Mutation; Myelofibrosis; Polycythaemia vera; Prognosis

Indexed keywords

JANUS KINASE 2; PROTEIN TYROSINE KINASE; JAK2 PROTEIN, HUMAN; ONCOPROTEIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTATIONAL ANALYSIS; MYELOFIBROSIS; MYELOID METAPLASIA; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYCYTHEMIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; SCORING SYSTEM; THROMBOCYTHEMIA; THROMBOSIS; ADOLESCENT; AGE; ENZYMOLOGY; GENETICS; METHODOLOGY; MIDDLE AGED; MUTATION; THROMBOCYTOSIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOFIBROSIS; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PROGNOSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; THROMBOCYTOSIS;

EID: 30844444135     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05776.x     Document Type: Article

References (52)

1. van den Akker E. van Dijk T.B. Schmidt U. Felida L. Beug H. Lowenberg B. von Lindern M. (2004) The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biological Chemistry, 385, 409 413.
2. Arcasoy M.O. Harris K.W. Forget B.G. (1999) A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation. Experimental Hematology, 27, 63 74.
3. Baxter E.J. Scott L.M. Campbell P.J. East C. Fourouclas N. Swanton S. Vassiliou G.S. Bench A.J. Boyd E.M. Curtin N. Scott M.A. Erber W.N. Green A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054 1061.
4. Brockman J.L. Schroeder M.D. Schuler L.A. (2002) PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Molecular Endocrinology, 16, 774 784.
5. Buschle M. Janssen J.W. Drexler H. Lyons J. Anger B. Bartram C.R. (1988) Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia, 2, 658 660.
6. Catlett-Falcone R. Landowski T.H. Oshiro M.M. Turkson J. Levitzki A. Savino R. Ciliberto G. Moscinski L. Fernandez-Luna J.L. Nunez G. Dalton W.S. Jove R. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10, 105 115.
7. Cervantes F. Pereira A. Esteve J. Rafel M. Cobo F. Rozman C. Montserrat E. (1997) Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. British Journal of Haematology, 97, 635 640.
8. Cervantes F. Barosi G. Demory J.L. Reilly J. Guarnone R. Dupriez B. Pereira A. Montserrat E. (1998) Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. British Journal of Haematology, 102, 684 690.
9. Cervantes F. Alvarez-Larran A. Talarn C. Gomez M. Montserrat E. (2002) Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. British Journal of Haematology, 118, 786 790.
10. Chaiter Y. Brenner B. Aghai E. Tatarsky I. (1992) High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leukemia and Lymphoma, 7, 251 255.
11. Chen Z. Notohamiprodjo M. Guan X.Y. Paietta E. Blackwell S. Stout K. Turner A. Richkind K. Trent J.M. Lamb A. Sandberg A.A. (1998) Gain of 9p in the pathogenesis of polycythaemia vera. Genes, Chromosomes and Cancer, 22, 321 324.
12. Dai C. Krantz S.B. (2001) Increased expression of the INK4a/ARF locus in polycythaemia vera. Blood, 97, 3424 3432.
13. De Vos J. Jourdan M. Tarte K. Jasmin C. Klein B. (2000) JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. British Journal of Haematology, 109, 823 828.
14. Deeg H.J. Gooley T.A. Flowers M.E. Sale G.E. Slattery J.T. Anasetti C. Chauncey T.R. Doney K. Georges G.E. Kiem H.P. Martin P.J. Petersdorf E.W. Radich J. Sanders J.E. Sandmaier B.M. Warren E.H. Witherspoon R.P. Storb R. Appelbaum F.R. (2003) Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood, 102, 3912 3918.
15. Dewald G.W. Broderick D.J. Tom W.W. Hagstrom J.E. Pierre R.V. (1985) The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders. Cancer Genetics and Cytogenetics, 18, 1 10.
16. Dupriez B. Morel P. Demory J.L. Lai J.L. Simon M. Plantier I. Bauters F. (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 88, 1013 1018.
17. Golde D.W. Bersch N. Cline M.J. (1977) Polycythemia vera: hormonal modulation of erythropoiesis in vitro. Blood, 49, 399 405.
18. Goldman J.M. (2005) A unifying mutation in chronic myeloproliferative disorders. New England Journal of Medicine, 352, 1744 1746.
19. James C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. Garcon L. Raslova H. Berger R. Bennaceur-Griscelli A. Villeval J.L. Constantinescu S.N. Casadevall N. Vainchenker W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144 1148.
20. Jones A.V. Kreil S. Zoi K. Waghorn K. Curtis C. Zhang L. Score J. Seear R. Chase A.J. Grand F.H. White H. Zoi C. Loukopoulos D. Terpos E. Vervessou E.C. Schultheis B. Emig M. Ernst T. Lengfelder E. Hehlman R. Hochhaus A. Oscier D. Silver R.T. Reiter A. Cross N.C.P. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood First Edition Paper, prepublished online 26 May 2005; DOI 10.1182/blood-2005-03-1320.
21. Kaushansky K. (2005) On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood, 105, 4187 4190.
22. Klingmuller U. Lorenz U. Cantley L.C. Neel B.G. Lodish H.F. (1995) Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell, 80, 729 738.
23. Kralovics R. Guan Y. Prchal J.T. (2002) Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythaemia vera. Experimental Hematology, 30, 229 236.
24. Kralovics R. Buser A.S. Teo S.S. Coers J. Tichelli A. der Maas A.P. Skoda R.C. (2003) Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood, 102, 1869 1871.
25. Kralovics R. Passamonti F. Buser A.S. Soon-Siong T. Tiedt R. Passweg J.R. Tichelli A. Cazzola M. Skoda R.C. (2005) A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. New England Journal of Medicine, 352, 1779 1790.
26. + cell fractions in myeloproliferative disorders with homozygous JAK2V617F in granulocytes. British Journal of Haematology, 130, 797 799.
27. Levine R.L. Wadleigh M. Cools J. Ebert B.L. Wernig G. Huntly B.J. Boggon T.J. Wlodarska I. Clark J.J. Moore S. Adelsperger J. Koo S. Lee J.C. Gabriel S. Mercher T. D'Andrea A. Frohling S. Dohner K. Marynen P. Vandenberghe P. Mesa R.A. Tefferi A. Griffin J.D. Eck M.J. Sellers W.R. Meyerson M. Golub T.R. Lee S.J. Gilliland D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythaemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387 397.
28. Mesa R.A. Hanson C.A. Rajkumar S.V. Schroeder G. Tefferi A. (2000) Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood, 96, 3374 3380.
29. Najean Y. Rain J.D. Billotey C. (1998) Epidemiological data in polycythaemia vera: a study of 842 cases. Hematology and Cell Therapy, 40, 159 165.
30. Najfeld V. Montella L. Scalise A. Fruchtman S. (2002) Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. British Journal of Haematology, 119, 558 566.
31. Okamura T. Kinukawa N. Niho Y. Mizoguchi H. (2001) Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. International Journal of Hematology, 73, 194 198.
32. Passamonti F. Malabarba L. Orlandi E. Barate C. Canevari A. Brusamolino E. Bonfichi M. Arcaini L. Caberlon S. Pascutto C. Lazzarino M. (2003) Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica, 88, 13 18.
33. Prchal J.F. Axelrad A.A. (1974) Letter: Bone-marrow responses in polycythaemia vera. New England Journal of Medicine, 290, 1382.
34. Reeder T.L. Bailey R.J. Dewald G.W. Tefferi A. (2003) Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood, 101, 1981 1983.
35. Roder S. Steimle C. Meinhardt G. Pahl H.L. (2001) STAT3 is constitutively active in some patients with polycythaemia rubra vera. Experimental Hematology, 29, 694 702.
36. Rupoli S. Da Lio L. Sisti S. Campanati G. Salvi A. Brianzoni M.F. S, D.A., Cinciripini A. Leoni P. (1994) Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Annals of Hematology, 68, 205 212.
37. Sandberg E.M. Ma X. He K. Frank S.J. Ostrov D.A. Sayeski P.P. (2005) Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophophorylation. Journal of Medicinal Chemistry, 48, 2526 2533.
38. Shannon K. Van Etten R.A. (2005) JAKing up hematopoietic proliferation. Cancer Cell, 7, 291 293.
39. Shultz L.D. Rajan T.V. Greiner D.L. (1997) Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnology, 15, 302 307.
40. Siena S. Bregni M. Brando B. Belli N. Ravagnani F. Gandola L. Stern A.C. Lansdorp P.M. Bonadonna G. Gianni A.M. (1991) Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood, 77, 400 409.
41. Silva M. Richard C. Benito A. Sanz C. Olalla I. Fernandez-Luna J.L. (1998) Expression of Bcl-x in erythroid precursors from patients with polycythaemia vera [see comments]. New England Journal of Medicine, 338, 564 571.
42. Socolovsky M. Fallon A.E. Wang S. Brugnara C. Lodish H.F. (1999) Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell, 98, 181 191.
43. Steensma D.P. Dewald G.W. Lasho T.L. Powell H.L. McClure R.F. Levine R.L. Gilliland D.G. Tefferi A. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ''atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood, 106, 1207 1209.
44. Tefferi A. (2000) Myelofibrosis with Myeloid Metaplasia. New England Journal of Medicine, 342, 1255 1265.
45. Tefferi A. (2003) Treatment approaches in myelofibrosis with myeloid metaplasia: The old and the new. Seminars in Hematology, 40, 18 21.
46. Tefferi A. Lasho T.L. Brockman S.R. Elliott M.A. Dispenzieri A. Pardanani A. (2004) FIP1L1-PDGFRA and c-kit D816 V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica, 89, 871 873.
47. Tefferi A. Lasho T.L. Schwager S.M. Strand J.S. Elliott M. Mesa R. Li C.-Y. Wadleigh M. Lee S.J. Gilliland D.G. (2005) The clinical and PRV-1 expression phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythaemia vera. Cancer (in press).
48. Vardiman J.W. Brunning R.D. Harris N.L. (2001) WHO histological classification of chronic myeloproliferative diseases. In: World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues (ed. by E.S. Jaffe N.L. Harris H. Stein J.W. Vardiman pp. 17 44. International Agency for Research on Cancer (IARC) Press, Lyon, France.
49. Westwood N.B. Gruszka-Westwood A.M. Atkinson S. Pearson T.C. (2001) Polycythemia vera: analysis of DNA from blood granulocytes using comparative genomic hybridization. Haematologica, 86, 464 469.
50. Yoon S.Y. Li C.Y. Mesa R.A. Tefferi A. (1999) Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 106, 682 688.
51. Zanjani E.D. Lutton J.D. Hoffman R. Wasserman L.R. (1977) Erythroid colony formation by polycythaemia vera bone marrow in vitro. Dependence on erythropoietin. Journal of Clinical Investigation, 59, 841 848.
52. Zhao R. Xing S. Li Z. Fu X. Li Q. Krantz S.B. Zhao Z.J. (2005) Identification of an acquired JAK2 mutation in polycythaemia vera. Journal of Biological Chemistry, 280, 22788 22792.